A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State. (September 2015)

• Record Type: Journal Article
• Authors: Small, David S.; Zhang, Wei; Royalty, Jane; Cannady, Ellen A.; Downs, Delyn; Friedrich, Stuart; Suico, Jeffrey G.
• Is Part Of: Journal of cardiovascular pharmacology and therapeutics. Volume 20:Number 5(2015:Sep.)
• Page Start: 483
• Page End: 489
• Publication Date: 2015-09
• Subjects: evacetrapib -- food effect -- cholesteryl ester transfer protein -- cholesterol; Cardiovascular pharmacology -- Periodicals; Cardiovascular system -- Diseases -- Treatment -- Periodicals; 616
• DOI: 10.1177/1074248415575153
• Languages: English
• ISSNs: 1074-2484

Abstract

Purpose: To determine the effect of a high-fat meal on evacetrapib exposure at steady state in healthy participants. Methods: This was a randomized, 2-period, 2-sequence, open-label, crossover study. Patients were randomly assigned to 1 of the 2 treatment sequences in which they received evacetrapib 130 mg/d for 10 days following a 10-hour fast each day or following a high-fat breakfast each day. Plasma samples collected through 24 hours were analyzed for evacetrapib concentrations and pharmacokinetic parameter estimates including area under the concentration–time curve during a dosing interval (AUCτ ), maximum observed concentration (Cmax ), and time of Cmax (tmax ) were calculated. Pharmacodynamic parameters, including cholesteryl ester transfer protein (CETP) activity, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, were also assessed. Results: A total of 34 males and 6 females, mean age 41.5 years and mean body mass index 26.6 kg/m 2, were enrolled. Statistical analysis showed AUCτ was 44% higher (90% confidence interval [CI]: 29%-62%) and Cmax was 51% higher (90% CI: 28%-79%) in the fed state than in the fasted state, indicating an effect of food. Consistent with higher evacetrapib exposure, changes in HDL-C, LDL-C, and CETP activity appeared to be greater in the fed state than in the fasted state. There were no notable changes in total cholesterol or triglycerides following administration in the fed and fasted states. The 130-mg doses of evacetrapib were well tolerated with and without food. Conclusion: A high-fat meal increased evacetrapib mean exposure at steady state by 44% in healthy participants.